.INVESTIGATION HIGHLIGHT.06 August 2024.
A big randomized regulated trial with cisgender ladies highlights the challenges of adherence to a daily oral preexposure treatment routine and demonstrates that twice-yearly shot of lenacapavir may maintain successful HIV prevention levels over 6 months.